Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Diabetes / Metabolic Rheumatology Gastroenterology Women's Health Mental Health / Psychiatry Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Phase IV NCT07402707

Dosing of Steroids for Acute Asthma Given in the Emergency Department – a Pilot Randomised Feasibility Trial of Dexamethasone in Children

Dosing of Steroids for Acute Asthma Given in the Emergency Department – a Pilot Randomised Feasibility Trial of Dexamethasone in Children — Recruiting • Phase IV • Respiratory…

📅 23 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase IV
NCT ID
NCT07402707
Sponsor
Sheffield Children's NHS Foundation Trust
Start
2026-02-23
ClinicaliQ Trial Snapshot
  • Dosing of Steroids for Acute Asthma Given in the Emergency Department – a Pilot Randomised Feasibility Trial of Dexamethasone in Children — Recruiting • Phase IV • Respiratory / COPD / Asthma • NCT07402707.
  • Sponsor: Sheffield Children's NHS Foundation Trust.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Steroids given by mouth are an important first line treatment for children presenting with asthma attacks. Dexamethasone is the steroid used in some emergency departments (EDs) because of the need for a single dose and as it is well tolerated. The dose of dexamethasone in treating asthma attacks is not clearly established. This study compares two different doses of dexamethasone in children presenting with an asthma attack. Investigators will compare the effect of two different doses in reducing the need for a repeat prescription of steroids for an asthma attack…

Eligibility Snapshot
  • : * Children aged 4-15 years (inclusive) presenting to the ED with an asthma exacerbation, where oral steroids are recommended by Trust/National guidelines. * Children whose parents/carers do not speak English will also be eligible provided they speak one of the common languages where an interpreter and Information Sheets are available (Slovakian, Arabic and Urdu).

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Mepolizumab for Treating Severe Refractory Eosinophilic Asthma (NICE TA431)
Respiratory / COPD / Asthma · 27 Mar 2026
Initiate mepolizumab 100 mg subcutaneously once monthly only in adults with severe eosinophilic asthma inadequately controlled on high-dose inhaled corticosteroids plus long-acting…
View guideline →
Guideline
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment
Respiratory / COPD / Asthma · 02 Apr 2026
Digital spirometry algorithms can improve diagnostic accuracy for asthma and COPD in primary care and community diagnostic centres, potentially reducing unnecessary referrals…
View guideline →
Guideline
GINA 2024 Report: Global Strategy for Asthma Management and Prevention
Respiratory / COPD / Asthma · 31 Mar 2026
GINA 2024 reinforces no SABA-only treatment for any asthma severity: all patients should receive ICS-containing controller therapy or ICS-formoterol MART as first-line…
View guideline →
Guideline
2021 ESCMID Guidelines for the Management of Community-acquired Pneumonia
Respiratory / COPD / Asthma · 30 Mar 2026
This ESCMID guideline addresses 2021 ESCMID Guidelines for the Management of Community-acquired Pneumonia in Respiratory / COPD / Asthma. Use it to…
View guideline →
Clinical Brief
Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines
Respiratory / COPD / Asthma · MHRA · 24 Apr 2025
Healthcare professionals and patients are reminded of the risk of severe asthma attacks and increased mortality associated with overuse of SABA with…
View brief →
Guideline
Dupilumab for Treating Moderate-to-Severe Atopic Dermatitis (NICE TA534)
Respiratory / COPD / Asthma · 27 Mar 2026
Initiate dupilumab in adults and adolescents aged 12+ with moderate-to-severe atopic dermatitis only when topical corticosteroids have failed or are inadvisable, using…
View guideline →